These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19285266)

  • 41. Binding properties of antagonists to cannabinoid receptors in intact cells.
    Wennerberg M; Cheng L; Hjorth S; Clapham JC; Balendran A; Vauquelin G
    Fundam Clin Pharmacol; 2011 Apr; 25(2):200-10. PubMed ID: 20608998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents.
    Lee HK; Choi EB; Pak CS
    Curr Top Med Chem; 2009; 9(6):482-503. PubMed ID: 19689362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cannabinoid
    Skolnick P; Crystal R
    J Neural Transm (Vienna); 2020 Feb; 127(2):279-286. PubMed ID: 31893308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists.
    Papanastasiou IP; Georgiadis MO; Iliopoulos-Tsoutsouvas C; Paronis CA; Brust CA; Tran NK; Ji L; Ma X; Wood JT; Zvonok N; Tong F; Bohn LM; Nikas SP; Makriyannis A
    Eur J Med Chem; 2022 Feb; 230():114027. PubMed ID: 35051750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Fluorescent Probe to Unravel Functional Features of Cannabinoid Receptor CB
    Martín-Fontecha M; Angelina A; Rückert B; Rueda-Zubiaurre A; Martín-Cruz L; van de Veen W; Akdis M; Ortega-Gutiérrez S; López-Rodríguez ML; Akdis CA; Palomares O
    Bioconjug Chem; 2018 Feb; 29(2):382-389. PubMed ID: 29314831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?
    Kunos G; Osei-Hyiaman D; Bátkai S; Sharkey KA; Makriyannis A
    Trends Pharmacol Sci; 2009 Jan; 30(1):1-7. PubMed ID: 19042036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders.
    Vinod KY; Hungund BL
    Expert Opin Ther Targets; 2006 Apr; 10(2):203-10. PubMed ID: 16548770
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nabilone administration in refractory chronic diarrhea: a case series.
    Pellesi L; Verga MC; De Maria N; Villa E; Pini LA; Guerzoni S
    BMC Gastroenterol; 2019 Jun; 19(1):105. PubMed ID: 31238887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England.
    Buggy Y; Cornelius V; Wilton L; Shakir SA
    Drug Saf; 2011 Jun; 34(6):501-9. PubMed ID: 21585222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ethnopharmacological approaches in mood and anxiety disorders. The relevance of the oxidative stress status.
    Foyet SH; Balmus IM; Hervé Hervé NA; Emmanuel AA; Guenne S; Kiendrebéogo M; Ciobica A
    J Complement Integr Med; 2017 Mar; 14(2):. PubMed ID: 28284035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Anxiogenic and depressogenic side-effects of non-psychiatric drugs].
    Kirilly E; Gonda X; Juhász G; Bagdy G
    Orv Hetil; 2013 Aug; 154(34):1327-36. PubMed ID: 23955968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective Reduction of THC's Unwanted Effects through Serotonin Receptor Inhibition.
    Robinson R
    PLoS Biol; 2015 Jul; 13(7):e1002193. PubMed ID: 26158526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Addiction: pregnenolone limits effects of cannabis.
    Welberg L
    Nat Rev Neurosci; 2014 Feb; 15(2):66-7. PubMed ID: 24434911
    [No Abstract]   [Full Text] [Related]  

  • 54. Neuropharmacology: Pain relief without pairing up.
    Carr F
    Nat Rev Neurosci; 2015 Sep; 16(9):508-9. PubMed ID: 26220481
    [No Abstract]   [Full Text] [Related]  

  • 55. Dronabinol-Induced Acute Altered Mental Status in an Elderly Patient.
    Sinha A; Singh P; Kupfer Y
    Am J Ther; 2018; 25(4):e502-e503. PubMed ID: 28452845
    [No Abstract]   [Full Text] [Related]  

  • 56. The psychiatric side-effects of rimonabant.
    Moreira FA; Crippa JA
    Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New approaches and challenges to targeting the endocannabinoid system.
    Di Marzo V
    Nat Rev Drug Discov; 2018 Sep; 17(9):623-639. PubMed ID: 30116049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
    Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
    Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.
    Morales P; Hernandez-Folgado L; Goya P; Jagerovic N
    Expert Opin Ther Pat; 2016 Jul; 26(7):843-56. PubMed ID: 27215781
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of endocannabinoid signaling in anxiety and depression.
    Patel S; Hillard CJ
    Curr Top Behav Neurosci; 2009; 1():347-71. PubMed ID: 21104391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.